Natural Killer (NK) Cells: Pushing the Next Wave of Immuno-oncology Therapies

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
The field of immuno-oncology has grown exponentially, leading to a host of new therapeutics being developed to recruit the immune system to fight cancer. While T cell-based therapies (BiTES and CARTs) have advanced the farthest, a new wave of drugs that recruit the innate immune system also hold remarkable promise to treat cancer patients with long-term success, but with less side effects.

Panelists will address the opportunities and challenges for these next-generation immuno-oncology drugs which could potentially change the game when it comes to engaging the immune system to kill tumors.
Moderator
photo
Principal, Cancer Cell Therapy Practice Lead
Cello Health BioConsulting (previously Defined Health)
Speakers
photo
CEO
Celularity
photo
CEO
Kleo Pharmaceuticals, Inc.
photo
Senior Director, Early Clinical Development Hematology/Oncology and Cell Therapy
Celgene/BMS